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DESIGN OF A MEASURE OF SATISFACTION WITH TREATMENT FOR MACULAR 
DEGENERATION (MACTSQ) 
Jan Mitchell, Leonie S. Brose, Clare Bradley, Psychology, Royal Holloway, University of London, 
Egham, Surrey, UK  
 
AIM: Several treatments for wet macular degeneration (MD) are now available and new treatments 
are being developed and evaluated. A measure of treatment satisfaction in MD patients is urgently 
needed. Design work on the MacTSQ is described. METHOD: A preliminary draft MacTSQ with 14 
items was prepared using an existing measure of treatment satisfaction in diabetic retinopathy 
(RetTSQ) as a starting point. Items were scored from 6 (e.g. very satisfied) to 0 (e.g. very 
dissatisfied). A final open question elicited any satisfaction or dissatisfaction not already covered. 
Participants (N=20; mean age 71 years; 13 women, 7 men), had received treatment for MD in the 
UK, including laser (N=3), photodynamic therapy (7), anti-VEGF injection (Lucentis or Avastin) (6), 
steroid injection (1), vitamin/mineral supplements (2) and acupuncture (1). They took part in semi-
structured interviews (recorded) to elicit their experience of MD and its treatment, before 
completing and commenting on the draft MacTSQ. RESULTS: During the interview process 2 
items were removed (less relevant for MD treatment): difficulty of treatment; influence over 
treatment. Three items relevant to MD patients were added: cost of treatment (some MD 
treatments are available to some patients only privately); difficulty of journey to clinic; experience of 
angiogram (for some the diagnostic test was more unpleasant than treatment). Two items were 
expanded or reworded to elicit more comprehensive data: e.g. adequacy and timing of information 
given about treatment (some interviewees reported information was not given, was too technical or 
was given too late to be of use). Perhaps surprisingly, the 6 patients who had had anti-VEGF 
intravitreal injections reported high levels of satisfaction with little or no discomfort or distress. 
Overall data indicated high levels of satisfaction across most domains for the 3 main treatment 
groups. CONCLUSION: The MacTSQ will be useful in clinical trials and routine clinical practice for 
a wide range of treatments. Use of the measure in a forthcoming clinical trial of anti-VEGF 
treatments will enable psychometric evaluation. 
